Important Dates
- Abstract Submission Deadline: September 20(Fri), 2024
- Abstract Acceptance Notification: October 7(Mon), 2024
- Pre-registration Deadline: October 25(Fri), 2024
Welcome Message
Dear friends and colleagues,
On behalf of the Korean Society of Medical Oncology (KSMO), and the Cholangiocarcinoma Foundation (CCF), we are pleased to invite you to participate in 2024 KSMO Liver Cancer Symposium & the 7th Asia-Pacific Cholangiocarcinoma Conference. This year's conference will be held at the Grand Intercontinental Seoul Parnas, Seoul, Republic of Korea, from November 2(Sat) to 3(Sun), 2024.
7th Asia-Pacific Cholangiocarcinoma Conference event aims to provide opportunities for interested individuals to learn more about the latest advances in research, treatment, and care of biliary tract cancer patients.
In addition, this year’s conference will be held in conjunction with the annual Liver Cancer Symposium that takes place in Republic of Korea. This integration will provide a comprehensive platform for sharing knowledge and fostering collaboration among experts in both cholangiocarcinoma and liver cancer.
The program will seek to develop sustainable participation of the medical and research communities from Asia-Pacific, US, and EU in the field of biliary tract cancers by:
We also request the participants to share their work and submit their abstracts. Important abstracts will be discussed during the conference oral presentation session and poster presentation session.
We encourage colleagues from around the world to participate in the conference.
We look forward to seeing you in Seoul.
7th Asia-Pacific Cholangiocarcinoma Conference event aims to provide opportunities for interested individuals to learn more about the latest advances in research, treatment, and care of biliary tract cancer patients.
In addition, this year’s conference will be held in conjunction with the annual Liver Cancer Symposium that takes place in Republic of Korea. This integration will provide a comprehensive platform for sharing knowledge and fostering collaboration among experts in both cholangiocarcinoma and liver cancer.
The program will seek to develop sustainable participation of the medical and research communities from Asia-Pacific, US, and EU in the field of biliary tract cancers by:
- Enhancing the comprehension and expertise of attendees on pivotal issues pertaining to the diagnosis, treatment, and care of cholangiocarcinoma.
- Identifying knowledge gaps and achieving consensus on the rapidly evolving advancements in basic, translational, and clinical research.
- Promoting interdisciplinary cooperation and the dissemination of best practices through the development, fortification, and support of collaborative efforts.
- Fostering scholarly dialogue and encouraging innovative approaches in the field.
We also request the participants to share their work and submit their abstracts. Important abstracts will be discussed during the conference oral presentation session and poster presentation session.
We encourage colleagues from around the world to participate in the conference.
We look forward to seeing you in Seoul.
Do-Youn Oh, M.D., PhD.
Conference Chairs,
The Korean Society of Medical Oncology (KSMO)
Eugene J. Koay, M.D., PhD.
Conference Chairs,
The Cholangiocarcinoma Foundation (CCF)
The Korean Society of Medical Oncology (KSMO)
The Korean Society of Medical Oncology (KSMO) was founded in November 2005 with the purpose of enhancing the quality of cancer patient care by promoting knowledge in clinical oncology and supporting collaboration and communication among clinical oncologists. As a representative body in the field of clinical oncology in Korea, KSMO has been consistently active in the academic sphere both domestically and internationally. Through the dedicated efforts of all our members and past executive committees, we have quickly grown to become the most trusted professional society for cancer diseases in the TBD. In 2018, we became a full member of the Korean Medical Association, serving a pivotal role in the field of internal medicine specializing in oncology.
The Korean Society of Medical Oncology (KSMO) was founded in November 2005 with the purpose of enhancing the quality of cancer patient care by promoting knowledge in clinical oncology and supporting collaboration and communication among clinical oncologists. As a representative body in the field of clinical oncology in Korea, KSMO has been consistently active in the academic sphere both domestically and internationally. Through the dedicated efforts of all our members and past executive committees, we have quickly grown to become the most trusted professional society for cancer diseases in the TBD. In 2018, we became a full member of the Korean Medical Association, serving a pivotal role in the field of internal medicine specializing in oncology.
The Cholangiocarcinoma Foundation (CCF)
The Cholangiocarcinoma Foundation’s (CCF) mission is to find a cure and improve the quality of life for those affected by cholangiocarcinoma (bile duct cancer). Founded in 2005 in Salt Lake City, UT, by a family who lost a loved one to cholangiocarcinoma, CCF has grown to become the leading global resource in research, education, and public awareness.
The International Cholangiocarcinoma Research Network (ICRN) is a global collaboration of research groups from renowned institutions who are working in concert to improve knowledge about cholangiocarcinoma etiology, prevention, early detection, treatment, and prognosis. The network is comprised of highly talented individuals from a spectrum of disciplines, perspectives, and research methods who share a passion for making significant scientific advances to improve outcomes for patients with cholangiocarcinoma.
The Cholangiocarcinoma Foundation’s (CCF) mission is to find a cure and improve the quality of life for those affected by cholangiocarcinoma (bile duct cancer). Founded in 2005 in Salt Lake City, UT, by a family who lost a loved one to cholangiocarcinoma, CCF has grown to become the leading global resource in research, education, and public awareness.
The International Cholangiocarcinoma Research Network (ICRN) is a global collaboration of research groups from renowned institutions who are working in concert to improve knowledge about cholangiocarcinoma etiology, prevention, early detection, treatment, and prognosis. The network is comprised of highly talented individuals from a spectrum of disciplines, perspectives, and research methods who share a passion for making significant scientific advances to improve outcomes for patients with cholangiocarcinoma.
Speakers
Choong-kun LeeYonsei University, Republic of Korea
Chung Ryul OhChung-Ang University Hospital, Republic of Korea
Dong Jin JooSeverance Hospital, Republic of Korea
Dong-Hwan JungAsan Medical Center, Republic of Korea
Eugene J. KoayMD Anderson Cancer Center, USA
Flavio G. RochaOregon Health & Science University, USA
Haley EllisMassachusetts General Hospital, USA
Hee Young NaSeoul National University Bundang Hospital, Republic of Korea
Hong Jae ChonCHA University Bundang Medical Center, Republic of Korea
Hye Jin ChoiYonsei Cancer Center, Republic of Korea
Hyo Cheol KimSeoul National University Hospital, Republic of Korea
Hyoung Don KimAsan Medical Center, Republic of Korea
Jae Hee ChoYonsei University, Republic of Korea
Jaekyung CheonAsan Medical Center, Republic of Korea
Jeesun YoonSeoul National Universtiy Hospital, Republic of Korea
Jeffrey H. LeeMD Anderson Cancer Center, USA
Jill KoshiolNational Cancer Institute, USA
Jin Won KimSeoul National University Bundang Hospital, Republic of Korea
Juan ValleThe Cholangiocarcinoma Foundation, USA
Juil ParkSeverance Hospital, Republic of Korea
Jung Yong HongSamsung Medical Center, Republic of Korea
Kristen SpencerNYU Grossman School of Medicine, USA
Kyubo KimSeoul National University Bundang Hospital, Republic of Korea
Leonard AngkaCanadian Cholangiocarcinoma Collaborative (C3), Canada
Li Tzong ChenKaohsiung Medical University, Taiwan
Louise ConnellMemorial Sloan Kettering Cancer Center, USA
Masafumi IkedaNational Cancer Center Hospital East, Japan
Melinda BachiniThe Cholangiocarcinoma Foundation, USA
Milind JavleMD Anderson Cancer Center, USA
Minsuk KwonSamsung Medical Center, Republic of Korea
Myung Ah LeeThe Catholic Univ. of Korea Seoul St.Mary's Hospital, Republic of Korea
Sang Hyub LeeSeoul National University Hospital, Republic of Korea
Seo Hee ChoiYonsei Cancer Center, Yonsei University, Republic of Kore
Shishir MaithelEmory University, USA
So Heun LeeChung-Ang University Gwang Myeong Hospital, Republic of Korea
Stacie LindseyThe Cholangiocarcinoma Foundation, USA
Subin HeoAsan Medical Center, Republic of Korea
Suebpong TanasanvimonChulalongkorn University, Thailand
Sunyoung LeeMD Anderson Cancer Center, USA
Tae Hyun KimNational Cancer Center, Republic of Korea
Tae-Yong KimSeoul National University Hospital, Republic of Korea
Teresa MacarullaVall d'Hebron Institute of Oncology, Spain
Vaibhav SahaiUniversity of Michigan Health, USA
Vikas OstwalTata Memorial Center, India
Young Nyun ParkYonsei University, Republic of Korea
Young Rok ChoiSeoul National University Hospital, Republic of Korea
Ash PatelThe Cholangiocarcinoma Foundation, USA
Cassian YeeMD Anderson Cancer Center, USA
